GW Pharmaceuticals PLC (GWPH)
(Delayed Data from NSDQ)
$175.50 USD
+2.34 (1.35%)
Updated May 3, 2019 04:00 PM ET
After-Market: $175.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$175.50 USD
+2.34 (1.35%)
Updated May 3, 2019 04:00 PM ET
After-Market: $175.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
New Strong Sell Stocks for May 6th
by Zacks Equity Research
OYST, CDAY, GWPH, HRTG, and NATI have been added to the Zacks Rank #5 (Strong Sell) List on May 6, 2021
Jazz Pharma (JAZZ) Q1 Earnings Beat, Sales Miss, Stock Down
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports mixed first-quarter 2021 results as earnings beat estimates while sales miss the same. Shares down
JAZZ's Xywav sNDA for Hypersomnia Gets FDA Priority Review
by Zacks Equity Research
JAZZ focuses on expanding label of its recently approved sleep drug, Xywav - a low sodium-formulation of Xyrem.
Best Performing ETFs of Q1 2021
by Neena Mishra
We highlight top performing ETF areas of the first quarter
Inside the Top-Performing ETFs of Q1
by Sweta Killa
Amplify Seymour Cannabis ETF (CNBS) topped the list of the best-performing ETFs of February with impressive returns of about 60%.
Jazz's (JAZZ) Vyxeos Gets FDA Nod for Pediatric Leukemia
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) gets FDA approval for label expansion of its cancer drug, Vyxeos, in pediatric patients with newly-diagnosed therapy-related acute myeloid leukemia.
Jazz Pharma (JAZZ) Q4 Earnings Miss, 2021 Sales View Dull
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports mixed fourth-quarter 2020 results as earnings miss estimates while sales beat the same. Shares down.
Should You Invest in Marijuana Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Cannabis Stocks Rise on Hopes of Federal Legalization in US
by Zacks Equity Research
Cannabis stocks seem poised to gain on hopes of removal of the federal ban on cannabis products under the new administration.
Cannabis ETFs Spike on Jazz-GW Pharma Deal
by Sweta Killa
Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.
Top ETF of November & Its Best Stocks
by Sweta Killa
Amplify Seymour Cannabis ETF (CNBS) topped the list of the best-performing ETFs of November with impressive returns of more than 47%.
Should You Buy Cannabis Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the recent developments in the space.
Why Cannabis Stocks & ETFs Are Soaring
by Neena Mishra
Marijuana stocks are rising on hopes of favorable regulatory environment
DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect weak segmental performance.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Why Earnings Season Could Be Great for GW Pharmaceuticals (GWPH)
by Zacks Equity Research
GW Pharmaceuticals (GWPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Invitae (NVTA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q3.
McKesson (MCK) to Post Q2 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
OPKO Health (OPK) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.
Livongo Health (LVGO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Livongo Health's (LVGO) third-quarter results are likely to reflect growth in core Livongo for Diabetes solution.
Baxter (BAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) third-quarter performance is likely to reflect growth in its Acute Therapies business.
Stryker (SYK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) third-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
What's in Store for Meridian Bioscience's (VIVO) Q3 Earnings?
by Trina Mukherjee
Meridian Bioscience's (VIVO) fiscal third-quarter results are likely to reflect strong performance by Life Science business line.
ABIOMED (ABMD) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
The commercial rollout of ABIOMED's (ABMD) Impella 5.5 is expected to have progressed steadily through the fiscal first quarter.
DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect weak segmental performance.